Johnson & Johnson (NYSE:JNJ - Get Free Report) shares traded down 1.2% on Thursday . The stock traded as low as $151.64 and last traded at $151.41. 1,150,234 shares changed hands during trading, a decline of 88% from the average session volume of 9,376,108 shares. The stock had previously closed at $153.18.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Finally, Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $170.88.
Check Out Our Latest Analysis on JNJ
Johnson & Johnson Price Performance
The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock's fifty day moving average price is $155.67 and its 200-day moving average price is $153.79. The firm has a market cap of $367.50 billion, a PE ratio of 22.96, a P/E/G ratio of 2.56 and a beta of 0.42.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.40%. Johnson & Johnson's payout ratio is 57.84%.
Insider Buying and Selling
In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.
Hedge Funds Weigh In On Johnson & Johnson
A number of hedge funds have recently made changes to their positions in JNJ. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. purchased a new position in Johnson & Johnson in the fourth quarter valued at about $29,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $32,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
